NewsFeeder
Headline News
- Reaction score
- 4
Why Oppenheimer Global fund is focusing on biotech as rates rise
The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc, Bluebird Bio Inc and Ionis Pharmaceuticals Inc whose drugs can have multiple uses rather than pinpointing a specific ailment.
https://finance.yahoo.com/news/why-oppenheimer-global-fund-focusing-040000464.html?.tsrc=rss
The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc, Bluebird Bio Inc and Ionis Pharmaceuticals Inc whose drugs can have multiple uses rather than pinpointing a specific ailment.
https://finance.yahoo.com/news/why-oppenheimer-global-fund-focusing-040000464.html?.tsrc=rss
